Format

Send to

Choose Destination
Crit Rev Oncol Hematol. 2012 Sep;83(3):393-406. doi: 10.1016/j.critrevonc.2011.11.004. Epub 2011 Dec 3.

Not all sarcomas developed in irradiated tissue are necessarily radiation-induced--spectrum of disease and treatment characteristics.

Author information

1
Department of Radiation Oncology/IBDC CNRS UMR 6543 Institut Universitaire de la Face et du Cou, Antoine-Lacassagne Cancer Center, Nice Sophia-Antipolis University, 33 Av. Valombrose, 06189 Nice Cedex 2, France. jthariat@hotmail.com

Abstract

BACKGROUND:

Sarcomas in irradiated tissue (SITs) are often considered with second cancers, although they usually present distinct dose-response, genetic and clinical patterns. The contribution of radiation in SIT development is likely, but remains unproven in many cases.

MATERIALS AND METHODS:

We reviewed the literature for published data on SITs.

RESULTS:

SITs incidence ranged between 0.03% and 0.2%. Median latency was 15 years. Angiosarcoma was the second most common subtype after undifferentiated sarcomas of malignant fibrous histiocytoma (MFH). C-Myc overexpression can be used to identify radiation-induced angiosarcoma, and a recently described transcriptomic signature of genes involved in chronic oxidative stress and mitochondrial dysfunction may indicate radiation causality. Osteosarcomas were often associated with genetic predisposition. Five-year survival rates rarely exceeded 30% because the therapeutic possibilities were often limited by the first cancer. Chemotherapy response may differ from that of de novo sarcomas.

CONCLUSION:

SITs present different characteristics from non-sarcomatoid second cancers. Reporting of SIT cases and the establishment of tissue and serum banks is necessary to better understand and validate the recently discovered radiation signature.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center